Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.64 |
| ▸ | DRD2 | P14416 | 12/20 | 0.64 |
| ▸ | HTR1A | P08908 | 11/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21642951 | 0.99 | DRD4 (0.62) | DRD4DRD2HTR1AKCNH2SIGMAR1 | |
| SCHEMBL28324996 | 0.82 | HTR1A (0.60) | DRD4DRD2HTR1AKCNH2SIGMAR1 | |
| SCHEMBL21662144 | 0.81 | DRD4 (0.61) | DRD4DRD2HTR1AKCNH2SIGMAR1 | |
| SCHEMBL21038280 | 0.80 | HTR1A (0.57) | DRD4DRD2HTR1AKCNH2 | |
| Hydrochloric Acid SCHEMBL30658434 | 0.80 | DRD4 (0.60) | DRD4DRD2HTR1AKCNH2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL21642941 | 0.80 | DRD4 (0.60) | DRD4DRD2HTR1AKCNH2SIGMAR1 | |
| SCHEMBL21642950 | 0.78 | HTR1A (1.00) | DRD4DRD2HTR1AKCNH2 | |
| SCHEMBL5149479 | 0.78 | HTR1A (0.53) | DRD4DRD2HTR1AKCNH2SIGMAR1 | |
| SCHEMBL3453155 | 0.77 | DRD4 (0.52) | DRD4DRD2HTR1AKCNH2SIGMAR1 | |
| SCHEMBL1138642 | 0.76 | DRD4 (0.52) | DRD4DRD2HTR1AKCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399308-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399308-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-11780820-B2 | 2,6-disubstituted pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-10 | — | — | US | disclosed |
| US-11780820-B2 | 2,6-disubstituted pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20210332025-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-10-28 | — | — | US | disclosed |
| US-11014905-B2 | 2,6-disubstituted pyridine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-10800755-B2 | 2,6-disubstituted pyridine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-13 | — | — | US | disclosed |
| US-20200239432-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| EP-3608314-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-20200039952-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332025-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | CNR1, CNR2, CRHR1 | DRD4 29/4885DRD2 12/4885HTR1A 7/4885 |
| US-20200039952-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | CNR1, CNR2, CRHR1 | DRD4 29/4885DRD2 12/4885HTR1A 7/4885 |
| US-20230399308-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | CNR1, CNR2, CRHR1 | DRD4 29/4885DRD2 12/4885HTR1A 7/4885 |
| US-11014905-B2 | 2,6-disubstituted pyridine derivative | CNR1, CNR2, CRHR1 | DRD4 29/4885DRD2 12/4885HTR1A 7/4885 |
| US-20200239432-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | CNR1, CNR2, CRHR1 | DRD4 29/4885DRD2 12/4885HTR1A 7/4885 |
| US-11780820-B2 | 2,6-disubstituted pyridine derivative | CNR1, CNR2, CRHR1 | DRD4 29/4885DRD2 12/4885HTR1A 7/4885 |
| US-10800755-B2 | 2,6-disubstituted pyridine derivative | CNR1, CNR2, CRHR1 | DRD4 29/4885DRD2 12/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.